| ||||
| MRCG/HRB Joint Funding Scheme |
| Monday, 13 December 2010 10:23 |
|
The Alpha One Foundation invites research proposals applications for consideration in the Medical Research Charities Group (MRCG) and Health Research Board (HRB) joint funding scheme 2011. This joint funding scheme has been in operation since 2006 and provides funding of up to €100,000 per annum for clearly defined research projects for up to 36 months. Smaller projects are also considered. For further information about applying for the joint funding scheme please contact Kitty O'Connor by email This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by phone on 01-8093871. Deadlines for submissions of applications is 5pm Friday the 21st of January 2011. |
Alpha-1 Antitrypsin is an important protein produced by the liver, which is released into the bloodstream and travels to the lungs. Once inside the lungs it provides protection from the destructive effects of infections and harmful irritants, particularly tobacco smoke.
Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, along with cystic fibrosis, is the commonest genetic lung disease in Ireland. It severely affects more than 2,000 people nationally, with another 10,000 individuals also at risk of lung and liver disease. It is the only proven genetic risk factor for COPD.